Mutations in the PITX2 bicoid-like homeobox gene cause Rieger syndrome. Rieger syndrome is an autosomal-dominant human disorder characterized by glaucoma, as well as dental hypoplasia, mild craniofacial dysmorphism and umbilical stump abnormalities. PITX2 has also been implicated in the development of multiple organs and left-right asymmetry in the body plan.
Introduction
The PITX2 gene was cloned based on its linkage in Rieger syndrome (1). Rieger syndrome is an autosomal-dominant human disorder characterized by ocular anterior chamber anomalies causing glaucoma in more than 50% of affected individuals, as well as dental hypoplasia, mild craniofacial dysmorphism and umbilical stump abnormalities (1, 2) . Other features associated with this syndrome include abnormal cardiac, limb and pituitary development. PITX2 has also been shown to be a downstream target in left-right asymmetry pathways and organogenesis (3, 4) . It is expressed asymmetrically to the left side during early development in the lateral plate mesoderm (LPM) and later in most of the organs derived from LPM, including the heart and the gut (4, 5) .
The PITX2 protein is a 33 kD protein that has a homeodomain similar in sequence to other bicoid binding homeodomain proteins, i.e. a characteristic lysine at residue 50 of the homeodomain (1) . Bicoidtype homeodomains have a TAATCC consensus binding site and PITX2 has been shown to specifically bind to this consensus sequence (6, 7, 8) . In addition, PITX2 transactivates a reporter gene with multimers of the bicoid binding site (6) . Amendt et al. (6) have shown that PITX2 interacts with Pit-1, an important transcription factor regulating expression of thyroid-stimulating hormone, growth hormone, and prolactin, and the terminal differentiation of the cell types in which they are expressed (9, 10) . Transient transfection assays with the prolactin promoter and both PITX2 and Pit-1 showed a strong synergistic effect on transactivation (6) .
It has been demonstrated that residue 50 of a given homeodomain interacts with base pairs 5 and 6 of the hexanucleotide consensus (11, 12, 13, 14) . Interestingly, a mutation found in a Rieger syndrome The 32 P-labeled probe for EMSAs was generated by annealing complementary oligonucleotides containing the sequence gatccGCACGGCCCATCTAATCCCGTGggatc and end-filled using Klenow polymerase with 32 P-dATP as described (17) . Standard binding assays were carried out by incubating the oligonucleotide probe (1.0 pmol) in a 20 µL reaction containing binding buffer (20 mM Hepes, pH 7.5, 5%
glycerol, 50 mM NaCl, 1 mM dithiothreitol), 0.1 µg of poly(dI-dC), and 100-300 ng protein on ice for 15 minutes. The samples were electrophoresed for 3.5 hours at 280 V on 8% polyacrylamide gels as described (6) .
Computer modeling
The structure of Antp homeodomain-DNA complex was obtained from the Protein Database ∆energy for termination = 0.05 kcal/mol), and the complex was reannealed around the residue change (dielectric constant = 80; ∆energy for termination = 0.05 kcal/mol; reannealing 'hot' radius = 6 Å, 'interesting' radius = 12 Å) and the entire complex minimized (dielectric constant = 80; ∆energy for termination = 0.005 kcal/mol). Total energy, E, of the entire complex was calculated using the Tripos force field, represented by the equation: E = ΣE str + ΣE bend + ΣE oop + ΣE tors + ΣE vdw + [ΣE ele + ΣE dist_c + ΣE ang_c + ΣE tors_c + ΣE range_c + ΣE multi + Σ E field fit ]. Where str = bond stretched or compressed from its equilibrium bond length; bend = bending bond angles from their equilibrium values; oop = bending planar atoms out of the plane; tors = torsion or twisting about bonds; vdw = van der Waals non-bonded interactions; ele = electrostatic interactions; dist_c = distance constraints; tors_c = torsion angle constraints; range_c = range constraints; multi = multifit.
Cell culture and reporter gene assays
The wildtype PITX2 (6), T68P (6) , and K88E cDNAs cloned into pcDNA3.1 MycHisC expression vector (Invitrogen) contain the cytomegalovirus (CMV) promoter and an in-frame C-terminal c-Myc epitope. The TK-Bic reporter contains the herpes simplex virus thymidine kinase minimal promoter with four bicoid elements (6) . The prolactin-luciferase reporter contains 2500 base pairs of the rat prolactin enhancer/promoter (19) . A CMV β-galactosidase (6) or an SV40 β-galactosidase (Promega) reporter plasmid was used as a control for transfection efficiency. The rat Pit-1 expression plasmid is under the control of the Rous sarcoma virus promoter (6 antibiotics. FuGene 6 (Roche) was used for COS7 (9 µL) and CHO cells (3 µL), whereas, Lipofectamine 2000 (Gibco BRL) was used for GH3 cells (4 µL). Assays used 0.5 µg of each construct for CHO and GH3 cells, while 1.5 µg of each construct were used for COS7 cells. The DNA was incubated with the corresponding transfection reagent in the absence of serum according to the manufacturer's protocol.
The DNA-transfection reagent mixture was added to cells growing in antibiotic-free media in the presence of serum and incubated for 16-20 hrs. Following incubation, the cells were scraped, lysed and assayed using luciferase assay reagents (Promega) and β-galactosidase assay reagents (Tropix Inc.). Luciferase activities were corrected for both transfection efficiency and protein levels (Bradford assays) (BioRad).
For western blots, equal amounts of cell extracts from transfection assays were electrophoresed on a 12.5% SDS-polyacrylamide gel, transferred to polyvinylidine difluoride filters (Millipore), and immunoblotted using a c-Myc antibody (Santa Cruz Labs) and ECL reagents (Amersham Pharmacia Biotech). Statistical significance was calculated using a simple t-test for means of two samples.
Results

Identification of the K88E mutation
The pedigree of the affected proband and family with a de novo mutation is shown in Figure 1a . The proband presented the characteristic Rieger syndrome features including small and dysplastic primary teeth (Fig. 1b) , protuberant umbilicus, and ocular anomalies. The initial eye exam was interpreted as possible bilateral Peter's anomaly, however, subsequent exams revealed a spectrum consistent with bilateral anterior segment dysgenesis more severe than those seen in many patients with Rieger syndrome. Single strand conformation polymorphism analysis of PITX2 exons in proband genomic DNA identified a heterozygous A→G change in codon 88 (Fig. 1c) resulting in a lysine (AAG) to glutamic acid (GAG) substitution. 
K88E is defective in DNA binding
We evaluated the DNA binding activity of the mutant PITX2 protein. Wildtype PITX2 has been shown to bind TAATCC bicoid consensus sequence in an electrophoretic mobility shift assay (EMSA) (Fig. 2a ) (6) . In contrast, the K88E mutant showed little or no binding to bicoid probe (Fig. 2a) . Similar amounts of bacterial-synthesized wildtype PITX2 and K88E mutant proteins were used (Fig. 2b) . EMSA was also done with similar amounts of wildtype and mutant PITX2 proteins obtained from in vitro transcription and translation (TNT) reactions ( Fig. 2c-d ). As seen with the bacterial-generated proteins, the K88E mutant protein had little or no binding to the bicoid probe. For comparison, the T68P mutant protein also showed greatly reduced binding under these conditions, in agreement with previous reports (6, 15) .
In order to get a better understanding of how the change from a lysine to a glutamic acid can result in significantly reduced DNA binding, we used a computer-modeling program to predict the PITX2 homeodomain-DNA complex structure (Fig. 3 ). There have been only three homeodomain-DNA complex structures determined through crystallization or NMR spectroscopy 2 . Of the three, we decided to model the PITX2 homeodomain after the Antennapedia (Antp) homeodomain-DNA complex primarily because it is one of the best characterized homeodomain proteins, the homeodomain is 43% identical to PITX2, and its DNA binding consensus sequence (TAATGG) closely matches that of PITX2 (TAATCC) (7, 14) . The
Antp homeodomain contains a glutamine at position 50 (Q50), which was shown to positively interact with positions 5 and 6 of its hexanucleotide consensus sequence (GG) (14) . We used the computer program SYBYL to substitute all the mismatched residues in the Antp homeodomain-DNA complex to those of the PITX2 homeodomain-DNA complex, including the substitution of Q50 to K50 and TAATGG to TAATCC, with recalculated local annealing and energy minimization. In the case of wildtype PITX2, K50 does not clash with positions 5 and 6 (Fig. 3) . However, the glutamic acid at position 50 causes an observable change in the spatial orientation of GG bases on the antisense strand of the TAATCC consensus sequence (Fig. 3) . The overall calculated energy for the K88E mutant homeodomain-DNA complex is 38 kcal/mole higher than wildtype PITX2 complex. The greatest contributions to the difference were from angle bending energy (∆E bend = 24.5 kcal/mol) and torsional energy (∆E tor = 21.4 kcal/mol).
K88E is defective in transactivation
Given the decreased DNA binding activity, we predicted that the K88E mutant protein would also have reduced transactivation activity. The transactivation activity of K88E protein was measured by transient transfection assays in COS7 and CHO cells, which do not express the endogenous PITX2 gene.
Wildtype PITX2 transactivated a luciferase reporter gene containing the thymidine kinase promoter with four TAATCC binding sites (TK-Bic) approximately 5-fold (Fig. 4a ). Wildtype PITX2 specifically activates this reporter and does not transactivate the parental TK-luciferase or the CMV-βgal reporter genes (6).
The K88E mutant did not appreciably transactivate the TK-Bic reporter (~1.3-fold) (Fig. 4a ). This is consistent with the reduced binding to the bicoid element in vitro. We then asked whether this defective transactivation was also manifested with a natural target, the prolactin promoter (Pro-Luc). Wildtype PITX2 activated the prolactin promoter approximately 8-fold in COS7 (6) and 13-fold in CHO (Fig. 4b) cells. In contrast, the K88E only weakly activated the prolactin promoter (~2-fold) in CHO cells (Fig. 4b ).
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K88E does not synergise with Pit-1
We also looked at the transactivation activity of the K88E mutant in the presence and absence of the POU homeodomain transcription factor, Pit-1. It has previously been shown that Pit-1 and PITX2 can synergistically activate the prolactin promoter (6) . The significance of the PITX2 interaction with Pit-1 is supported by their coexpression in early pituitary development and the phenotype of Pitx2 knockout mice (24, 25) . Coexpression of Pit-1 with wildtype PITX2 yielded about 350-fold transactivation of the prolactin reporter plasmid in CHO cells (Fig. 5a , lane 4). In contrast, the K88E mutant did not synergize with Pit-1
. This is similar to the T68P mutant, which also failed to synergise with Pit-1 (Fig. 5a , lane 10) (6).
K88E suppresses wildtype PITX2 synergism with Pit-1
In order to explain the marked phenotype of the patient carrying the K88E mutation, we tested the possibility that the mutant protein might interfere with the wildtype protein activity. Indeed, the presence of one wildtype and one mutant allele in Rieger syndrome can be viewed as an autosomal dominant as well as haploinsufficiency disorder. To simulate this situation, we co-transfected equal amounts of wildtype PITX2 and K88E mutant DNA with either the TK-Bic (Fig. 4a) or prolactin ( Fig. 4b ) reporter plasmids and found no significant effect on wildtype activity. We then repeated the same experiments in the presence of Pit-1. Surprisingly, the K88E mutant protein suppressed the synergistic effect of wildtype PITX2 with Pit-1 significantly (Fig. 5, lane 8) . In contrast, the T68P mutant did not suppress the synergism of wildtype PITX2 with Pit-1 (Fig. 5, lane 11) . As a control for the increased amount of transfected DNA, transfection with additional wildtype PITX2 DNA yielded similar activity as seen with 5 µg wildtype PITX2 (Fig. 5, lane 5) . As additional controls, K88E did not suppress the co-transfected CMV β-galactosidase or an SV40 β-galactosidase reporters. Titration of the K88E mutant DNA in the cotransfection assay indicated that approximately equimolar amounts of wildtype and K88E DNAs are required for significant inhibition of wildtype PITX2 activity (Fig. 6) . Again, titration of the T68P mutant DNA did not result in any inhibition of wildtype synergism (Fig. 6) . In order to confirm the dose-dependent nature of the dominant-negative effect, we transfected additional wildtype PITX2 DNA to the equimolar amounts of wildtype and K88E (Fig. 7) . The additional amount of wildtype DNA was able to significantly rescue the dominant-negative effect ( We wanted to know if K88E could suppress Pit-1 independent activation of the prolactin promoter.
We used a constitutively active MEK kinase (MEKK), which stimulates the MAP (mitogen activated protein) kinase signal transduction pathway, to activate the prolactin promoter in CHO cells (Fig. 8, lane 2). The K88E mutant was not able to suppress the MEKK stimulated activation of the prolactin promoter (Fig. 8, lane 3) . Thus, the dominant negative effect of K88E requires Pit-1 DNA binding or its interaction with PITX2 or both.
In order to determine the dependence of this dominant-negative effect on Pit-1 DNA binding, cotransfections of wildtype and mutant PITX2 were done in the presence of Pit-1 with TK-Bic reporter construct which lacks the Pit-1 binding site in COS7 cells (Fig. 9 ). Wildtype PITX2 activated the TK-Bic reporter approximately 5-fold (Fig. 9 , lane 2) as shown in Fig. 4 , while both K88E (Fig. 9 , lane 5) and T68P (Fig. 9, lane 7) showed little or no transactivation. As expected, the presence of Pit-1 did not affect the transactivation of wildtype PITX2 (Fig. 9 , lane 4), K88E (Fig. 9 , lane 6), or T68P (Fig. 9, lane 8) .
Cotransfection of the wildtype and the K88E mutant in the absence of Pit-1 (Fig. 9, lane 9 ) or in the presence of Pit-1 (Fig. 9 , lane 10) did not show any dominant negative effect. Likewise, the T68P mutant was not dominant negative as expected (Fig. 9, lanes 11, 12) . This implies that the Pit-1 binding site is required for the dominant negative effect.
In order to map the protein domains required for the K88E suppression of wildtype activity, we tested several Pit-1 and PITX2 mutants (Fig. 10 ). PITX2 ∆C39 lacks the C-terminal 39 amino acids that have been shown to interact with Pit-1 (6). Pit-1 ∆8-128 lacks the N-terminal 120 amino acid residues that constitute the major transactivation domain (20) . These N-terminal residues have been shown to interact with the closely related PITX1 (10). Pit-1 ∆POU lacks the POU-specific domain of Pit-1 required for DNA binding (21) . Finally, Pit-1 W261C contains the mutation identified in the Snell dwarf mice that disables the POU DNA domain (22) . Figure 10 shows the cotransfection of wildtype PITX2 and K88E mutant in the presence of Pit-1 mutants with the prolactin reporter in CHO cells. Wildtype PITX2 (Fig. 10, lane 2) and wildtype Pit-1 (Fig. 10, lane 3) show approximately 15-fold activation of prolactin promoter.
Cotransfection of both PITX2 and Pit-1 showed a synergistic response of approximately 60-fold ( Surprisingly, in CHO cells, PITX2 ∆C39 showed a strong synergism with Pit-1 (Fig. 10, lane7 ) which was suppressed by cotransfection of K88E (Fig. 10 , lane 8, p < 0.001). The Pit-1 ∆8-128 mutant (Fig. 10, lane   9 ) that lacks the major transactivation domain showed significantly reduced activity than wildtype Pit-1 (Fig. 10, lane 3 , p < 0.0004). Interestingly, this mutant which lacks the reported PITX1 interaction domain was also able to synergize with wildtype PITX2 (Fig. 10, lane 10) . This synergism was again suppressed by K88E mutant coexpression (Fig. 10, lane 11) . The PITX2 C∆39 lesser degree (about 3-fold) than seen with wildtype Pit-1 (6-fold) (Fig. 10, lanes 14 and 17 respectively) .
These results are consistent with the trend seen in Fig. 4b where coexpression of wildtype PITX2 and K88E mutant resulted in lower, albeit statistically non-significant (p < 0.14) transactivation. Results from
Figures 9 and 10 thus show that both Pit-1 binding site and Pit-1 DNA binding activity are required for a pronounced dominant negative effect. Furthermore, the K88E suppression of PITX2-Pit-1 synergism does not require the respective C-terminal or N-terminal domains of these proteins.
K88E suppresses prolactin promoter activity in GH3 cells
We wanted to see if K88E mutant would suppress the activity of endogenous Pitx2 and Pit-1. For this experiment, we used the GH3 pituitary cell line. GH3 cells are known to express the endogenous Pitx2
and Pit-1 genes (10). Under our conditions, overexpression of wildtype PITX2 (Fig. 11a, lane 2 (Fig. 11a, lane 4) was able to significantly suppress the prolactin promoter activity in GH3 cells (p < 0.005). In contrast, overexpression of the T68P mutant did not affect promoter activity (Fig. 11a, lane   5) . As a control, we used the TK-Bic reporter (Fig. 11b ) which lacks Pit-1 binding site. Neither the K88E or T68P mutants were able to suppress the activity of TK-Bic reporter in GH3 cells (Fig. 11b) . This control underscores the need for the Pit-1 binding site for the dominant negative effect of K88E mutant.
Hence the K88E mutant can repress wildtype PITX2 activity in both heterologous cells and in cells that normally express the Pitx2 gene. Furthermore, in both situations, Pit-1 interaction with DNA is required for repression by the K88E mutant.
Discussion
In this study we have focused on a point mutation, K88E, that changes a single amino acid in the recognition helix of the homeodomain from a lysine to a glutamic acid. We show that the K88E mutant is defective in its capacity to bind DNA and transactivate synthetic and natural promoters in transfection assays. Our computer modeling suggests that the defect in DNA binding of the K88E mutant homeodomain is due to the steric constraints which require significant unfavorable bending and torsional angles in the DNA. This energetic penalty results in a very large decrease in the binding constant.
Although the exact value of the energy difference (∆E = 38 kcal/mol) must be considered more qualitative than quantitative, a ∆E of this size would result in a decrease in the binding constant by about 30 orders of magnitude. Interestingly, the only documented homeodomain proteins with a glutamic acid at position 50 are Zmhox1a and Zmhox1b maize proteins that appear to bind very divergent sequences (26 Previous studies have indicated that PITX2 can form homodimers (6, 27) . One mechanism for the dominant negative inhibition would be that the K88E protein could heterodimerize with wildtype PITX2
and that the wildtype PITX2-K88E heterodimer would be unable to synergise with Pit-1. Simply interpreted, our results imply that wildtype PITX2-K88E mutant dimers are nonfunctional. At face value, this would explain the dominant-negative effect of K88E. However, the repression cannot be that simple since the suppression of wildtype PITX2 in CHO cells was significant only in the presence of Pit-1 DNA binding activity. Hence, it seems likely that the wildtype PITX2-K88E heterodimer is still able to bind DNA. Furthermore, the T68P mutant has decreased DNA binding, defective transactivation and synergism (6, 15 ), yet it is not a dominant-negative mutant protein.
We propose that the dominant negative nature of the PITX2-K88E wildtype-mutant heterodimer is dictated by its inability to synergise with other transcription factors, such as Pit-1. In support of this hypothesis, K88E was unable to suppress Pit-1 independent activation of the prolactin promoter by a constitutively active MEK kinase. Interestingly, the suppression by K88E requires a functional, but not physical, interaction between PITX2 and Pit-1. The C-terminal domain of PITX2 that binds Pit-1 is not required for repression by K88E. In this regard, we found that the requirement for the C-terminal 39 residues for synergism is cell-specific. It appears that these residues are not required for synergism in at least 3 cell lines, CHO, LS8, and N2A, but are required in COS7 and HeLa cells. The basis for this specificity is not known, but is suggestive that other factors are involved in PITX2 transactivation, as we had previously speculated based on data from the PITX2 ∆C39 mutant (6) . We have now shown that both PITX2 ∆C39, which lacks the Pit-1 interacting residues (6), and Pit1 ∆8-128, which lacks the reported PITX1 interacting residues (10), are capable of synergism in CHO cells and that this synergism can be suppressed by K88E.
In a further test of the role that Pit-1 plays in K88E suppression, we have shown that Pit-1 DNA binding activity is required. This was shown by complementary experiments using a reporter lacking a Pit-1 binding site (TK-bicoid) and by using mutant Pit-1 proteins that lack DNA binding activity (Pit-1 ∆POU and Pit-1 W261C). Taken together, these data imply that in CHO cells, Pit-1 and PITX2 DNA binding activities may be sufficient for the dominant negative effect of K88E. Finally, we showed that K88E can suppress the prolactin promoter in the pituitary adenoma GH3 cell line which expresses the endogenous Pit-1 and Pitx2 genes. The ability of K88E to suppress the prolactin promoter in GH3 cells supports the potential physiological relevance of K88E activity in the pituitary.
Our results describe the first molecular characterization of a dominant negative missense mutation in a homeodomain. The other examples of dominant negative mutations in homeodomain proteins have been truncations that remove the transactivation domain yet retain the DNA binding homeodomain (28, 29, 30) . Hence, the K88E mutation represents a new type of homeodomain mutation in human disorders. We propose that the phenotypic variation of Rieger syndrome can be determined by a continuum of mutations in PITX2 ranging from null deletions (1) 
